1-9 of 9
Denise Trone
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3 -ITD–mutated, relapsed or refractory AML

Clinical Trials & Observations
Jorge E. Cortes, Martin S. Tallman, Gary J. Schiller, Denise Trone, Guy Gammon, Stuart L. Goldberg, Alexander E. Perl, Jean-Pierre Marie, Giovanni Martinelli, Hagop M. Kantarjian, Mark J. Levis
Journal: Blood
Blood (2018) 132 (6): 598–607.
https://doi.org/10.1182/blood-2018-01-821629
Published: 2018
Includes: Supplemental data
Journal Articles

Laboratory and Clinical Investigations to Identify the Optimal Dosing Strategy for Quizartinib (AC220) Monotherapy in FLT3-Itd-Positive (+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Mark J. Levis, MD PhD, Jorge E. Cortes, MD, Guy M. Gammon, MBBS, MRCP, Denise Trone, Dongwoo Kang, Jianke Li
Journal: Blood
Blood (2016) 128 (22): 4042.
https://doi.org/10.1182/blood.V128.22.4042.4042
Published: 2016
Journal Articles

Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical AML Database (UK NCRI data)

Robert K Hills, DPhil, Guy Gammon, MBBS,MRCP, Denise Trone, Alan K. Burnett, MD FRCP
Journal: Blood
Blood (2015) 126 (23): 2557.
https://doi.org/10.1182/blood.V126.23.2557.2557
Published: 2015
Journal Articles

Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation

Brenda M. Sandmaier, MD, Samer K Khaled, MD, Betul Oran, MD, Guy Gammon, MD, Denise Trone, Olga Frankfurt, MD
Journal: Blood
Blood (2014) 124 (21): 428.
https://doi.org/10.1182/blood.V124.21.428.428
Published: 2014
Journal Articles

Results Of a Phase 1 Study Of Quizartinib (AC220, ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Jessica K Altman, MD, James M. Foran, MD, Keith W. Pratz, MD, Denise Trone, Guy Gammon, MD, Jorge E. Cortes, MD, Martin S Tallman, MD
Journal: Blood
Blood (2013) 122 (21): 623.
https://doi.org/10.1182/blood.V122.21.623.623
Published: 2013
Journal Articles

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Martin S Tallman, MD, Gary Schiller, MD, Denise Trone, Guy Gammon, MD, Stuart Goldberg, MD, Alexander E Perl, MD, Jean-Pierre Marie, MD, Giovanni Martinelli, Mark Levis, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 494.
https://doi.org/10.1182/blood.V122.21.494.494
Published: 2013
Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Alexander E Perl, MD, Hervé Dombret, MD, Sabine Kayser, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 48.
https://doi.org/10.1182/blood.V120.21.48.48
Published: 2012
Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

Mark J. Levis, MD, PhD, Alexander E Perl, MD, Hervé Dombret, MD, Hartmut Döhner, MD, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Jorge E Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 673.
https://doi.org/10.1182/blood.V120.21.673.673
Published: 2012
Journal Articles

Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status

Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, James M. Foran, MD, FRCPC, Darejan Ghirdaladze, Mamia Zodelava, Gautam Borthakur, M.D., Guy Gammon, MD, Denise Trone, Robert C Armstrong, Ph.D., Joyce James, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1507.
https://doi.org/10.1182/blood.V120.21.1507.1507
Published: 2012